Alpha-Synuclein Models of Parkinson’s Disease (PD)
We offer preclinical studies with the alpha-synuclein fibril seeding mouse model. This model has become an industry-standard for the evaluation of novel therapeutics for Parkinson’s Disease (PD) and other synucleinopathies, such as Lewy Body Dementia and Multiple System Atrophy. We offer inoculation of pre-formed fibrils (PFFs) into transgenic (M83 mice with A53T mutation) and non-transgenic (wild-type) mice.
This well-characterized model involves the seeding and spreading of recombinant αSyn fibrils or human brain extracts from an inoculation site to anatomically-connected brain regions. Various clinical phenotypes are induced depending on injection site, from motor deficits to olfactory and sleep alterations. This neurodegeneration model also demonstrates brain atrophy by MRI, elevation of neurofilament light (NfL) in plasma & CSF, and neuroinflammation.
This rodent model is used in preclinical efficacy assessments of therapeutics related to
- Misfolded α-synuclein aggregates
At Biospective, we offer preclinical studies with our well-characterized and validated in-house models, as well as with commercially-available and sponsor-provided models. Our end-to-end preclinical studies include breeding, housing, dosing, in vivo imaging (MRI & PET), behavior and functional assessments, and immunohistochemistry (IHC).